View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 13, 2022updated 27 Jul 2022 12:50pm

GenScript and ACT partner to develop new CAR-T cell therapies

The ACT platform will be commissioned to manufacture raw materials for the subsequent pipeline of ACT.

GenScript ProBio has signed a strategic collaboration memorandum of understanding (MoU) with ACT Therapeutics to develop a next-generation chimeric antigen receptor (CAR)-T cell therapy platform.

Through this collaboration, the companies have agreed to bolster their cooperation in the cell therapy field. 

GenScript and ACT are working on the signing of a contract for developing and manufacturing plasmid and virus vector for the first pipeline of ACT’s advanced CAR-T Platform (ACT platform).

This platform will be commissioned to manufacture raw materials for the subsequent pipeline of ACT.

An advanced CAR-T technology with a next-generation structure, the ACT platform targets existing blood cancer by bypassing the immune suppression microenvironment of solid cancer and stimulating surrounding immune cells. 

With the signing of the MoU, GenScript became a worldwide partner that can support ACT platforms for ACT therapeutics.

The platform is an immune cell-based next-generation cell and gene therapy technology that leverages virus vectors to insert genes targeting cancer antigens into immune cells.

GenScript possesses a high-quality virus vector process development and one-stop service platform for GMP manufacturing needed for developing cell and gene therapies.

ACT Therapeutics CEO Seogkyoung-Kong said: “We have completed preparations for the ACT platform to emerge globally through a strategic partnership with GenScript ProBio. 

“We will accelerate the development of treatments targeting refractory and intractable solid cancers.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology